Total Payments
$7,495
2024 Payments
$49.75
Companies
58
Transactions
426
Medicare Patients
3,401
Medicare Billing
$1.3M
Payment Breakdown by Category
Food & Beverage$6,224 (83.0%)
Education$871.73 (11.6%)
Consulting$400.00 (5.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,224 | 398 | 83.0% |
| Education | $871.73 | 20 | 11.6% |
| Consulting Fee | $400.00 | 1 | 5.3% |
| Unspecified | $0 | 7 | 0.0% |
Payments by Type
General
$7,495
419 transactions
Ownership
$0
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $538.55 | 36 | $0 (2020) |
| Genentech USA, Inc. | $524.88 | 36 | $0 (2024) |
| Daiichi Sankyo Inc. | $442.38 | 4 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $417.41 | 26 | $0 (2021) |
| Janssen Biotech, Inc. | $410.23 | 22 | $0 (2022) |
| PFIZER INC. | $386.32 | 33 | $0 (2020) |
| SANOFI-AVENTIS U.S. LLC | $338.82 | 7 | $0 (2022) |
| Pharmacyclics LLC, An AbbVie Company | $325.04 | 17 | $0 (2020) |
| Celgene Corporation | $314.12 | 20 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $312.41 | 21 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $49.75 | 3 | Genentech USA, Inc. ($27.75) |
| 2023 | $12.70 | 2 | Kite Pharma, Inc. ($12.70) |
| 2022 | $198.90 | 3 | SANOFI-AVENTIS U.S. LLC ($99.95) |
| 2021 | $162.61 | 7 | Epizyme, Inc., ($99.95) |
| 2020 | $849.96 | 33 | Daiichi Sankyo Inc. ($400.00) |
| 2019 | $2,112 | 143 | Genentech USA, Inc. ($164.60) |
| 2018 | $1,737 | 109 | Novartis Pharmaceuticals Corporation ($149.24) |
| 2017 | $2,372 | 126 | Genentech USA, Inc. ($216.32) |
All Payment Transactions
426 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/30/2024 | Janssen Pharmaceuticals, Inc | RYBREVANT (Drug) | Education | In-kind items and services | $22.00 | General |
| Category: Oncology | ||||||
| 01/26/2024 | Genentech USA, Inc. | Phesgo (Biological) | Food and Beverage | In-kind items and services | $27.75 | General |
| Category: BioOncology | ||||||
| 2024 | Cornerstone Specialty Network LLC | — | — | — | $0.00 | Ownership |
| 01/05/2023 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $12.70 | General |
| 2023 | Cornerstone Specialty Network LLC | — | — | — | $0.00 | Ownership |
| 12/12/2022 | SANOFI-AVENTIS U.S. LLC | JEVTANA (Drug) | Education | In-kind items and services | $99.95 | General |
| Category: Oncology | ||||||
| 04/27/2022 | Janssen Biotech, Inc. | DARZALEX (Biological) | Education | In-kind items and services | $98.95 | General |
| Category: Oncology | ||||||
| 2022 | Cornerstone Specialty Network LLC | — | — | — | $0.00 | Ownership |
| 11/10/2021 | Helsinn Therapeutics (U.S.), Inc. | AKYNZEO (Drug) | Education | In-kind items and services | $14.96 | General |
| Category: ONCOLOGY | ||||||
| 10/26/2021 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Education | In-kind items and services | $12.37 | General |
| Category: Oncology | ||||||
| 10/26/2021 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Education | In-kind items and services | $12.37 | General |
| Category: Oncology | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 05/11/2021 | Epizyme, Inc., | TAZVERIK (Drug) | Education | In-kind items and services | $99.95 | General |
| Category: ONCOLOGY | ||||||
| 03/18/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | In-kind items and services | $11.04 | General |
| Category: Oncology | ||||||
| 2021 | Cornerstone Specialty Network LLC | — | — | — | $0.00 | Ownership |
| 11/16/2020 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Education | In-kind items and services | $12.45 | General |
| Category: Oncology | ||||||
| 07/27/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | Cash or cash equivalent | $14.95 | General |
| Category: Oncology | ||||||
| 03/10/2020 | Daiichi Sankyo Inc. | Enhertu (Drug) | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| Category: Oncology | ||||||
| 03/09/2020 | Dova Pharmaceuticals | Doptelet (Drug) | Food and Beverage | In-kind items and services | $11.75 | General |
| Category: Hematology/Oncology | ||||||
| 03/06/2020 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $14.31 | General |
| Category: Oncology | ||||||
| 03/04/2020 | PFIZER INC. | INLYTA (Drug), BAVENCIO, BRAFTOVI | Food and Beverage | In-kind items and services | $11.06 | General |
| Category: ONCOLOGY | ||||||
| 03/03/2020 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $14.97 | General |
| Category: Oncology | ||||||
| 02/27/2020 | Amgen Inc. | XGEVA (Biological) | Food and Beverage | In-kind items and services | $16.51 | General |
| Category: Oncology | ||||||
| 02/26/2020 | Astellas Pharma US Inc | XOSPATA (Drug) | Food and Beverage | In-kind items and services | $22.37 | General |
| Category: ONCOLOGY | ||||||
| 02/25/2020 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $13.32 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 703 | 15,199 | $702,279 | $179,946 |
| 2022 | 21 | 851 | 18,131 | $996,670 | $301,585 |
| 2021 | 25 | 934 | 16,821 | $1.3M | $448,468 |
| 2020 | 25 | 913 | 16,777 | $986,623 | $329,151 |
Total Patients
3,401
Total Services
66,928
Medicare Billing
$1.3M
Procedure Codes
91
All Medicare Procedures & Services
91 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 197 | 451 | $103,670 | $45,305 | 43.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 16 | 2,280 | $147,120 | $42,405 | 28.8% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 20 | 3,061 | $85,950 | $18,798 | 21.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 73 | 111 | $33,723 | $16,117 | 47.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 34 | 117 | $71,006 | $12,992 | 18.3% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 13 | 6,890 | $56,290 | $9,503 | 16.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 34 | 38 | $16,019 | $5,445 | 34.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 28 | 28 | $12,376 | $5,002 | 40.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 55 | 65 | $9,960 | $4,626 | 46.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 23 | 61 | $9,625 | $3,988 | 41.4% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 13 | 60 | $18,787 | $3,346 | 17.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 25 | 59 | $17,241 | $3,274 | 19.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 26 | 220 | $21,000 | $2,919 | 13.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 58 | 236 | $20,034 | $2,765 | 13.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 13 | 47 | $6,836 | $1,166 | 17.1% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 11 | 41 | $3,925 | $717.74 | 18.3% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 14 | 28 | $1,920 | $555.80 | 28.9% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 17 | 600 | $63,960 | $503.97 | 0.8% |
| 96523 | Irrigation of implanted venous access drug delivery device | Office | 2023 | 12 | 20 | $2,118 | $442.97 | 20.9% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 21 | 786 | $718.50 | $77.10 | 10.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 28 | 3,780 | $170,100 | $64,585 | 38.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 202 | 625 | $153,125 | $63,052 | 41.2% |
| Q5111 | Injection, pegfilgrastim-cbqv, biosimilar, (udenyca), 0.5 mg | Office | 2022 | 12 | 360 | $258,120 | $49,276 | 19.1% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2022 | 21 | 4,380 | $100,740 | $28,280 | 28.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 46 | 197 | $65,010 | $23,279 | 35.8% |
About Dr. Mohammad Pazooki, MD
Dr. Mohammad Pazooki, MD is a Hematology & Oncology healthcare provider based in Hartford, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/20/2008. The National Provider Identifier (NPI) number assigned to this provider is 1881851616.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mohammad Pazooki, MD has received a total of $7,495 in payments from pharmaceutical and medical device companies, with $49.75 received in 2024. These payments were reported across 426 transactions from 58 companies. The most common payment nature is "Food and Beverage" ($6,224).
As a Medicare-enrolled provider, Pazooki has provided services to 3,401 Medicare beneficiaries, totaling 66,928 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 91 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Hartford, CT
- Active Since 05/20/2008
- Last Updated 01/15/2013
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1881851616
Products in Payments
- JEVTANA (Drug) $470.15
- Enhertu (Drug) $400.00
- Imbruvica (Drug) $325.04
- KEYTRUDA (Biological) $293.37
- OPDIVO (Biological) $252.41
- DARZALEX (Biological) $221.46
- Abraxane (Drug) $169.48
- Cabometyx (Drug) $147.93
- Revlimid (Drug) $130.74
- KISQALI (Drug) $121.73
- XTANDI (Drug) $116.07
- MEKINIST (Drug) $115.72
- SIR-Spheres Microspheres (Device) $113.74
- ADCETRIS (Biological) $112.39
- Neulasta (Biological) $104.84
- GAZYVA (Biological) $104.63
- XARELTO (Drug) $101.06
- TAZVERIK (Drug) $99.95
- TECENTRIQ (Biological) $97.20
- Lenvima (Drug) $95.68
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Hartford
Madhavi Gorusu, M.d, M.D
Hematology & Oncology — Payments: $399,570
Hematology & Oncology $399,570
Mr. Todd Alekshun, M.d, M.D
Hematology & Oncology — Payments: $83,681
Hematology & Oncology $83,681
Paul Dekker, Md, MD
Hematology & Oncology — Payments: $10,781
Hematology & Oncology $10,781
Yelena Pristyazhnyuk
Hematology & Oncology — Payments: $8,961
Hematology & Oncology $8,961
Stephen Firshein, Md, MD
Hematology & Oncology — Payments: $7,343
Hematology & Oncology $7,343
Susan Rabinowe, Md, MD
Hematology & Oncology — Payments: $6,991
Hematology & Oncology $6,991